Moreover, a retrospective cohort study of patients with Lynch syndrome who are carriers of a pathogenic germline mutation in the MLH1, MSH2, MSH6, or PMS2 gene reported that aspirin use was associated with a decreased risk of colorectal cancer (for 1 month to 4.9 years: HR, 0.49, 95% C, 0.27–0.90; for ≥ 5 years: HR, 0.25; 95% CI, 0.10–0.62) [46]. This evidence concerns the gene MLH1 and Lynch syndrome.